Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.48 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.48 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21968424 | 0.85 | PTGS2 (0.51) | PTGS2NAPRTEGFRABCC9ABCC8 | |
| SCHEMBL15625451 | 0.82 | PTGS2 (0.56) | PTGS2NAPRTEGFRNLRP3SLC1A3 | |
| SCHEMBL28079452 | 0.81 | RAB9A (0.50) | PTGS2NAPRTEGFRABCC9ABCC8 | |
| SCHEMBL25394823 | 0.80 | PTGS2 (0.62) | PTGS2NAPRTEGFRNLRP3SLC1A3 | |
| SCHEMBL20307210 | 0.80 | PTGS2 (0.51) | PTGS2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL13764330 | 0.80 | PPARA (0.57) | PTGS2PTGS1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL26282749 | 0.79 | PTGS2 (0.54) | PTGS2NAPRTEGFRNLRP3SLC1A3 | |
| SCHEMBL30591339 | 0.79 | PTGS2 (0.54) | PTGS2NAPRTEGFRNLRP3SLC1A3 | |
| SCHEMBL19630996 | 0.79 | NLRP3 (0.55) | PTGS2NAPRTEGFRNLRP3SLC1A3 | |
| SCHEMBL20078190 | 0.79 | MMP1 (0.46) | PTGS2NAPRTEGFRABCC9ABCC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-9949965-B2 | Tricyclic indole Mcl-1 inhibitors and uses thereof | VANDERBILT UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | PTGS2 682/4885NAPRT 4163/4885EGFR 786/4885 |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | PTGS2 1652/4885NAPRT 3205/4885EGFR 1273/4885 |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | PTGS2 682/4885NAPRT 4163/4885EGFR 786/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | PTGS2 682/4885NAPRT 4163/4885EGFR 786/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | PTGS2 1652/4885NAPRT 3205/4885EGFR 1273/4885 |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | PTGS2 1652/4885NAPRT 3205/4885EGFR 1273/4885 |
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | PTGS2 787/4885NAPRT 1903/4885EGFR 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.